Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 3 , Pages 177-179 , May 2006

Making prostate-specific antigen testing more effective

References 

  1. American Cancer Society. Cancer facts & figures. Available at: www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf. Accessed October 27, 2005.
  2. Ries LAG, Eisner MP, Kosary CL, et al., editors. SEER Cancer Statistics Review, 1975–2002. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2002/. November 2004 SEER data submission, posted to the SEER website 2005. Accessed October 27, 2005.
  3. Fang J , Metter EJ , Landis P , et al.   Low levels of prostate-specific antigen predict long-term risk of prostate cancer (Results from the Baltimore Longitudinal Study of Aging) . Urology . 2001;58:411–416
  4. Loeb S , Roehl KA , Antenor JAV , et al.   Baseline PSA compared with median for age group as predictor of pathologic tumor features in men <60 years of age . J Urol . 2005;173(Suppl 4):145
  5. Kundu SD , Grubb RL , Roehl KA , et al.   Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml . J Urol . 2005;173:1116–1120
  6. Catalona WJ , Smith DS , Ratliff TL , et al.   Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening . JAMA . 1993;270:948–954
  7. Freedland SJ , Aronson WJ , Kane CK , et al.   Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels . Cancer . 2004;101:748–753
  8. Krumholtz JS , Carvalhal GF , Ramos CG , et al.   Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features . Urology . 2002;60: 469–7
  9. Epstein JI , Walsh PC , Carmichael M , et al.   Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer . JAMA . 1994;271:368–374
  10. Ohori M , Wheeler TM , Dunn JK , et al.   The pathological features and prognosis of prostate cancer detectable with current diagnostic tests . J Urol . 1994;152:1714–1720
  11. Thompson IM , Pauler DK , Goodman PJ , et al.   Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter . N Engl J Med . 2004;350:2239–2246
  12. Schroder FH , van der Cruijsen-Koeter I , de Koning HJ , et al.   Prostate cancer detection at low prostate specific antigen . J Urol . 2000;163:806–812
  13. Raaijmakers R , Blijenberg BG , Finlay JA , et al.   Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml (Value of percent free prostate specific antigen on tumor detection and tumor aggressiveness) . J Urol . 2004;171:2245–2249
  14. Stamey TA , Caldwell M , McNeal JE , et al.   The prostate specific antigen era in the United States is over for prostate cancer (What happened in the last 20 years?) . J Urol . 2004;172:1297–1301
  15. Ramos CG , Roehl KA , Antenor JA , et al.   Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer . J Urol . 2004;172:137–140
  16. Mitchell RE , Shah JB , Desai M , et al.   Preoperative PSA lost the ability to predict biochemical failure after radical retropubic prostatectomy? . J Urol . 2005;173(Suppl 4):256; [Abstract 948]
  17. D’Amico AV , Chen MH , Roehl KA , et al.   Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy . N Engl J Med . 2004;351:125–135
  18. Carter HB , Pearson JD , Metter EJ , et al.   Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease . JAMA . 1992;267:2215–2220
  19. Fang J , Metter EJ , Landis P , et al.   PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml . Urology . 2002;59:889–893
  20. Berger AP , Diebl M , Steiner H , et al.   Longitudinal PSA changes in men with and without prostate cancer (Assessment of prostate cancer risk) . J Urol . 2005;173(Suppl 4):402
  21. Yu X , Han M , Gashti SN , et al.   Comparison of different methods for calculating PSA velocity (Importance of time interval prior to diagnosis of prostate cancer) . J Urol . 2005;173(Suppl):469

PII: S1078-1439(05)00223-1

doi: 10.1016/j.urolonc.2005.09.001

Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 3 , Pages 177-179 , May 2006

Article Tools